Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Sci-Tech Press Iceland.
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire, Inc.
·
February 27, 2025
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30...
VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management
GlobeNewswire, Inc.
·
March 4, 2025
VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- VIVUS, LLC., a biopharmaceutical company committed to the development and...
Alvogen Completes Comprehensive Refinancing with Longer-Dated Maturity Profile and Reduction of Debt
GlobeNewswire, Inc.
·
March 10, 2025
REYKJAVIK, Iceland and MORRISTOWN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Alvogen Pharma US, Inc. (“Alvogen” or the “Company”), a privately owned US-based pharmaceutical company, has completed a comprehensive refinancing of its capital...
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire, Inc.
·
May 23, 2025
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing...
Orchard Therapeutics Announces Reimbursement Agreement in Spain
GlobeNewswire, Inc.
·
February 28, 2025
LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has recently reached an agreement with the Interministerial Commission for the Pricing of Medicines of the Directorate of...
AirAsia partners with Plan3 to transform the passenger experience during flight disruptions
EIN Presswire
·
February 13, 2025
Enhancing Passenger Support with Innovative Disruption Management Solutions. REYKJAVIK, 105, ICELAND, February 13, 2025 /EINPresswire.com/ -- Flight delays and cancellations affect hundreds of millions of passengers each year, costing the global...
Oculis to Present at Upcoming March Investor Conference
GlobeNewswire, Inc.
·
March 5, 2025
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending...
Landmark Study Identifies New Genetic Cause of Neurodevelopmental Disorders, Bringing Long-Awaited Answers to Families
GlobeNewswire, Inc.
·
April 10, 2025
New York, NY, April 10, 2025 (GLOBE NEWSWIRE) -- A seminal study from researchers at the Icahn School of Medicine at Mount Sinai and their collaborators in the United Kingdom, Belgium, Spain, the Netherlands, and Iceland has uncovered a new...
Trump Media Alerts SEC to Potential Manipulation of DJT stock
GlobeNewswire, Inc.
·
April 17, 2025
SARASOTA, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) ("TMTG" or "the Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand...
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
GlobeNewswire, Inc.
·
February 28, 2025
If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
GlobeNewswire, Inc.
·
February 21, 2025
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI SELARSDI is...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
GlobeNewswire, Inc.
·
February 21, 2025
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI SELARSDI is...
NATO Allies must not reward the aggressor but must ensure a just and durable peace in Ukraine
NATO Parliamentary Assembly
·
May 26, 2025
25 May 2025 DAYTON, OHIO – Negotiations for a just and durable peace in Ukraine must be pursued with unity and resolve and must not reward the aggressor, undermine Ukraine’s sovereignty, or embolden authoritarian regimes, the NATO Parliamentary...
BlueCat appoints Peter Brennan as Chief Revenue Officer
GlobeNewswire, Inc.
·
February 26, 2025
TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of Intelligent Network Operations solutions that help organizations modernize, optimize, and secure their network infrastructure, announced Peter Brennan as its new...
Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
GlobeNewswire, Inc.
·
February 12, 2025
First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year Reimbursement agreement for Libmeldy® reached with...
The Arctic Institute’s Knowledge Production in the Arctic Series 2025: An Introduction
The Arctic Institute
·
May 20, 2025
Back to Publications The production of Arctic knowledge requires a negotiation between different forms of knowledge. Photo: Tom Öhlin The production of knowledge in and about the Arctic is inherently contested. While some work has explored the...
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
GlobeNewswire, Inc.
·
November 7, 2024
REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s...
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
GlobeNewswire, Inc.
·
November 4, 2024
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK...
Herring Market Gains Momentum, Eyes $10.57 Billion by 2034 with Strong Aquaculture Demand
GlobeNewswire, Inc.
·
February 24, 2025
Rockville , Feb. 24, 2025 (GLOBE NEWSWIRE) -- According to an updated research report by Fact.MR, the global herring market is projected to get to a value of US$ 9.27 billion in 2024 and further expand at a CAGR of 1.3% from 2024 to 2034. Herring...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
GlobeNewswire, Inc.
·
February 14, 2025
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...